This study investigates the efficacy and safety of two different OIT schemes to treat milk and egg allergic children
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of adverse events with an oFASS5 severity ≥2 occurred until Induction Phase (Part 1) completion at the hospital setting per subject in both groups, rush vs conventional
Timeframe: Throughout the Induction Phase (Part 1), 1 week up to 7 months
Proportion of subjects completing the Induction Phase (Part 1) in both groups (rush vs conventional) at the end of study (7 months of treatment)
Timeframe: End of study (7 months of treatment)